Key result
Simulated KCNQ1 antibody-based therapy rescued the prolonged QT interval in long QT syndrome type 2 but did not reduce the vulnerable window, indicating proarrhythmic risks.
Why the study?
Long QT interval syndrome can lead to sudden cardiac death, but its underlying mechanism remains largely unknown.
Does KCNQ1 antibody therapy improve cardiac electrophysiology and reduce arrhythmia vulnerability in a virtual heart model of Long QT syndrome type 2?
Does KCNQ1 antibody therapy improve cardiac electrophysiology and reduce arrhythmia vulnerability in a virtual heart model of Long QT syndrome type 2?
In a computational model of LQTS2, KCNQ1 antibody therapy shortened the QT interval but failed to reduce the vulnerable window, suggesting potential proarrhythmic risks.
KCNQ1 antibody may shorten QT in LQTS2 models but leaves arrhythmic vulnerability unresolved; hypothesis-generating for targeted immunotherapy.
Objective: Long QT interval syndrome (LQTS) is a highly dangerous cardiac disease that can lead to sudden cardiac death; however, its underlying mechanism remains largely unknown. This study is conceived to investigate the impact of two general genotypes of LQTS type 2, and also the therapeutic effects of an emerging immunology-based treatment named KCNQ1 antibody. Methods: A multiscale virtual heart is developed, which contains multiple biological levels ranging from ion channels to a three-dimensional cardiac structure with realistic geometry. Critical biomarkers at different biological levels are monitored to investigate the remodeling of cardiac electrophysiology induced by mutations. Results: Simulations revealed multiple important mechanisms that are hard to capture via conventional clinical techniques, including the augmented dispersion of repolarization, the increased vulnerability to arrhythmias, the impaired adaptability in tissue to high heart rates, and so on. An emerging KCNQ1 antibody-based therapy could rescue the prolonged QT interval but did not reduce the vulnerable window. Conclusions: Tiny molecular alterations can lead to cardiac electrophysiological remodeling at multiple biological levels, which in turn contributes to higher susceptibility to lethal arrhythmias in long QT syndrome type 2 patients. The KCNQ1 antibody-based therapy has proarrhythmic risks notwithstanding its QT-rescuing effects.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) studied Long QT syndrome type 2. KCNQ1 antibody was evaluated on Cardiac electrophysiology remodeling (QT interval and vulnerable window). Simulated KCNQ1 antibody-based therapy rescued the prolonged QT interval in long QT syndrome type 2 but did not reduce the vulnerable window, indicating proarrhythmic risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: